You are here

Alprolix

Biogen explores sale of hemophilia assets -sources

Yahoo/Reuters

Fri, 04/8/16 - 09:59 pm

Biogen's Surprising Weakness

Motley Fool

Sat, 09/12/15 - 01:29 pm

3 Reasons That Biogen's Shares Could Rise

Investopedia

Wed, 06/17/15 - 10:05 am

Alzheimer's disease

Are These Biogen Idec's Next Blockbusters?

Investopedia

Tue, 03/10/15 - 08:10 am

Biogen prices new, long-acting hemophilia med with eye on patient-switching

Fierce Pharma Marketing

Wed, 07/9/14 - 05:15 pm

patient-switching

Biogen Hemophilia Drugs Launch Into The Unknown

Investors.com

Mon, 06/30/14 - 05:53 pm

Biogen shares could rise 20% on robust drug pipeline, Barron's contends

The Fly on the Wall

Fri, 05/23/14 - 06:58 am

The price is right for patient-switching on Biogen's new hemophilia med Alprolix

Fierce Pharma

Tue, 04/22/14 - 09:30 am

Exclusive: Biogen prices hemophilia drug on par with older therapies

Yahoo/Reuters

Sat, 04/19/14 - 10:02 am

Biogen prices hemophilia drug on par with older therapies

Yahoo/Reuters

Fri, 04/18/14 - 04:38 pm

Biogen hemophilia nod puts Baxter's to-be-spun-off biopharma unit on notice

Fierce Pharma

Mon, 03/31/14 - 04:42 pm

Baxter International

Biogen Wins Approval for Long-Lasting Hemophilia B Treatment

Bloomberg

Sat, 03/29/14 - 09:10 am

Biogen Idec: More Pipeline Success, More Upside

Barron's

Thu, 03/6/14 - 10:30 am

Here's Why Biogen Could Be in Store for a Big 2014

Motley Fool

Wed, 02/12/14 - 06:48 pm

Biogen Idec says FDA will allow 3 more months to review its hemophilia B drug Alprolix

Yahoo/AP

Mon, 12/2/13 - 10:15 am